SCHEMBL25729591

SCHEMBL25729591

CCC(C)C(=O)NCC(F)C(C)(C)OCCOCCOCCOCCOCC(C)=O

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23945665 0.90 CES2 (0.33) CES2MEN1KMT2A
SCHEMBL25704177 0.89 MEN1 (0.31) MEN1KMT2A
SCHEMBL21106816 0.88 MEN1 (0.33) CES2MEN1KMT2A
SCHEMBL21105783 0.85 MEN1 (0.37) MEN1KMT2A
SCHEMBL24763970 0.85 MEN1 (0.37) MEN1KMT2A
SCHEMBL22790985 0.84 CES2 (0.33) CES2
SCHEMBL25924698 0.84 MEN1 (0.36) MEN1KMT2A
SCHEMBL23945865 0.84 MEN1 (0.31) MEN1KMT2A
SCHEMBL22856497 0.83 CES2 (0.34) CES2
SCHEMBL26400213 0.83 KDM4E (0.40) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 US disclosed
US-20230144292-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CES2 1669/4885MEN1 4055/4885KMT2A 445/4885
US-20230144292-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CES2 1669/4885MEN1 4055/4885KMT2A 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.